Tumor-infiltrating Treg cells display heightened PD-1 expression, which is dependent on the activation of SREBP, revealing a potential strategy for targeting Treg cell lipid metabolism for cancer immunotherapy [176]. This evidence concerns the gene PDCD1 and neoplasm.